[1. PERRIN P., CAILLARD S., JAVIER RM., et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. American Journal of Transplantation. 2013; 13(10): 2653-2663.10.1111/ajt.1242524034142]Search in Google Scholar
[2. MAZZAFERRO S., PASQUALI M., TAGGI F., et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clinical Journal of the American Society of Nephrology. 2009; 4(3): 685-690.10.2215/CJN.03930808265365719211668]Search in Google Scholar
[3. GWINNER W., SUPPA S., MENGEL M., et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. American Journal of Transplantation. 2005; 5(8): 1934-1941.10.1111/j.1600-6143.2005.00938.x15996242]Search in Google Scholar
[4. Cohen JB., Gordon CE., Balk EM., Francis JM., et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: A systematic review and meta-analysis. Transplantation. 2012; 94(10): 1041-1048.10.1097/TP.0b013e31826c396823069843]Search in Google Scholar
[5. PASCHOALIN RP., TORREGROSA JV., SÁNCHEZ-ESCUREDO A., BARROS X., DURÁN CE., CAMPISTOL JM., et al Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up. Transplantation Proceedings. 2012; 44(9): 2588-2589.10.1016/j.transproceed.2012.09.04923146463]Search in Google Scholar
[6. LINDBERG J.S., CULLETON B., WONG G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology. 2005; 16(3): 800-807.10.1681/ASN.200406051215689407]Search in Google Scholar
[7. PALMER S.C., NISTOR I., CRAIG J.C., et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Medicine. 2013; 10(4).10.1371/journal.pmed.1001436364008423637579]Search in Google Scholar
[8. PASCHOALIN R.P., TORREGROSA J.V., BARROS X., DURAN C.E., CAMPISTOL J.M. et al. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplantation proceedings. 2012; 44(8): 2376-2378.10.1016/j.transproceed.2012.07.04923026597]Search in Google Scholar
[9. TORREGROSA J.V., MORALES E., DIAZ J.M., et al. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology. 2014; 19(2): 84-93.10.1111/nep.1218624428216]Search in Google Scholar
[10. MESSA P., CAFFORIO C., ALFIERI C., et al. Clinical impact of hypercalcemia in kidney transplant. International Journal of Nephrology. 2011; 2011:9.10.4061/2011/906832313280221760999]Search in Google Scholar
[11. MUIRHEAD N., ZALTMAN J.S., GILL J.S., et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clinical Transplantation. 2014; 28(2): 161-165.10.1111/ctr.1229124329899]Search in Google Scholar
[12. TORREGROSA J.V., BARROS X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013; 33(6): 751-757.]Search in Google Scholar
[13. EVENEPOEL P., CLAES K., KUYPERS D.R., DEBRUYNE F., VANRENTERGHEM Y., et al. Parathyroidectomy after successful kidney transplantation: a single center study. Nephrology Dialysis Transplantation. 2007; 22(6): 1730-1737.10.1093/ndt/gfm04417371780]Search in Google Scholar
[14. ROJAS E., CARLINI R.G., CLESCA P., et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney International. 2003; 63(5): 1915-1923.10.1046/j.1523-1755.2003.00938.x12675872]Search in Google Scholar
[15. NAGANO N., NEMETH E.F. Functional proteins involved in regulation of intracellular Ca2+ for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetic. Journal of Pharmacological Sciences. 2005; 97(3): 355-360.10.1254/jphs.FMJ04007X615781990]Search in Google Scholar
[16. LINDBERG J.S., CULLETON B., WONG G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology. 2005; 16(3): 800-807.10.1681/ASN.200406051215689407]Search in Google Scholar
[17. GUERRA R., SAAVEDRA I.A., FERNANDEZ E.J., et al. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with Cinacalcet. Journal of Nephrology. 2011; 24(1): 78-82. 10.5301/JN.2010.293]Search in Google Scholar